The ongoing row over access in the U.K. to a Vertex (VRTX) Pharmaceuticals (VRTX) cystic fibrosis treatment has taken an unexpected twist, with a member of parliament challenging the government to issue a compulsory license so that a lower-cost version of the medicine could eventually become available.

In a statement, MP Bill Wiggins suggested the government pursue a so-called Crown Use license that could pave the way for an alternative supply of the Orkambi treatment, “because Vertex refused the largest ever financial offer the National Health Service has made in its entire history for this medicine.” And he noted the NHS offered approximately $650 million over five years for patient access.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • U.K. government and Vertex Pharmaceuticals

    Cfs die while we await your outcomes . fast tracked coffins..

    Triple drugs combo that will be out 2019 the uk should be in it to win it !!

    10 Per cent of cfs these drugs dont work so Vertex Pharmaceuticals needs more drugs on the market ..
    So why stop these drugs when also more advance drugs and gene mapping treatments should be next step and more tablets based items !

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy